Dupixent 300 MG/2 ML pen 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26F9KG3
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $53,273
Award facts
- Contract value 100% obligated
- $53,273.33 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $53,273.33 delivery order to AmerisourceBergen Drug Corp on January 8, 2026, for the supply of Dupixent 300 mg/2 ml pens (2 ml units). This is a firm fixed-price, non-set-aside contract with an ultimate completion date of January 9, 2026, and performance to be executed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic immunosuppressant medication used to treat moderate-to-severe atopic dermatitis, eosinophilic esophagitis, and asthma. The delivery order is issued under AmerisourceBergen's parent company, Cencora, Inc., which holds a $999,999,999.00 Indefinite Delivery Contract with DLA Troop Support Medical extending through December 31, 2031, serving as the primary vehicle for pharmaceutical and medical supply procurement supporting military healthcare programs globally.
This contract reflects the ongoing pharmaceutical supply chain support provided to the Department of Defense through the DLA Medical Supply Chain. AmerisourceBergen, operating as a subsidiary of Cencora, is a major pharmaceutical distributor and serves as a critical vendor for federal medical procurement, particularly for military treatment facilities and veteran healthcare systems. The firm fixed-price delivery order structure, coupled with the established IDC relationship, demonstrates the company's capability to efficiently fulfill specialized pharmaceutical requirements across multiple therapeutic domains for federal government health programs.
Quick answers
Who was awarded contract SPE2DR26F9KG3?
SPE2DR26F9KG3 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 8, 2026.
How much is contract SPE2DR26F9KG3 worth?
The government has obligated $53,273 on SPE2DR26F9KG3.
Is contract SPE2DR26F9KG3 an order under another contract?
Yes. SPE2DR26F9KG3 is a delivery order under SPE2DR25D2206, an indefinite delivery contract.
Was contract SPE2DR26F9KG3 competed?
The extent of competition for SPE2DR26F9KG3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award